This company is no longer active
8STN Stock Overview
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sorrento Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$2.79 |
| 52 Week Low | US$0.13 |
| Beta | 2.12 |
| 1 Month Change | 0% |
| 3 Month Change | 19.20% |
| 1 Year Change | -80.28% |
| 3 Year Change | -91.94% |
| 5 Year Change | -95.22% |
| Change since IPO | -94.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8STN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -11.3% | 3.0% |
| 1Y | -80.3% | -15.0% | 19.3% |
Return vs Industry: 8STN underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 8STN underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8STN volatility | |
|---|---|
| 8STN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8STN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8STN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 949 | Henry Ji | www.sorrentotherapeutics.com |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Sorrento Therapeutics, Inc. Fundamentals Summary
| 8STN fundamental statistics | |
|---|---|
| Market cap | €154.45m |
| Earnings (TTM) | -€626.04m |
| Revenue (TTM) | €56.58m |
2.7x
P/S Ratio-0.2x
P/E RatioIs 8STN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8STN income statement (TTM) | |
|---|---|
| Revenue | US$60.71m |
| Cost of Revenue | US$233.93m |
| Gross Profit | -US$173.23m |
| Other Expenses | US$498.42m |
| Earnings | -US$671.64m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -285.36% |
| Net Profit Margin | -1,106.41% |
| Debt/Equity Ratio | -55.7% |
How did 8STN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/31 10:38 |
| End of Day Share Price | 2023/03/03 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sorrento Therapeutics, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| James Molloy | Alliance Global Partners |
| Difei Yang | Brean Capital |